Literature DB >> 31343610

Prediction of lymph node metastasis by PET/CT metabolic parameters in patients with esophageal squamous cell carcinoma.

Manman Xu1, Ling Wang2, Mingli Ouyang1, Jie Lin1, Lili Wang1, Xiangwu Zheng1, Shouliang Miao1, Kun Tang1.   

Abstract

OBJECTIVE: The aim of this study was to investigate the capability of F-FDG PET/computed tomography (CT)-related metabolic parameters to predict lymph node metastasis (LNM) and occult lymph node metastasis (OLNM) in patients with esophageal squamous cell carcinoma (ESCC).
METHODS: Totally 84 patients undergoing curative esophagectomy with lymph node dissection were enrolled in this study. Metabolic tumor volume (MTV) was measured using threshold-based methods with a threshold of 40% maximum standardized uptake value (SUVmax). The derivative of the volume (V)-threshold (T) function (volume difference/threshold difference) was defined as the heterogeneity factor (HF). In addition, SUVmax, SUVmean, total lesion glycolysis (TLG), maximum tumor-to-blood SUV ratio (SURmax), SURmean and several clinicopathologic parameters were analyzed to identify risk factors of LNM and OLNM.
RESULTS: SUVmax, SUVmean, MTV, TLG, SURmax, SURmean and HF were significantly different between LNM (+) and LNM (-). The optimal cut-off values of those parameters were 12.5, 8.34, 15.01, 117.185, 7.885, 4.855 and 0.300, respectively. Logistic regression analysis showed that MTV (OR = 1.127, P = 0.04) and SURmax (OR = 1.446, P = 0.004) were independent predictors of LNM, with sensitivity and specificity were 51.2%, 83.7% vs. 53.7%, 79.1%. In univariate and multivariate analysis, MTV was the sole parameter associated with OLMN (P = 0.024).
CONCLUSION: MTV and SURmax were statistically significant predictors of LNM in patients with ESCC, while MTV was a predictor of OLNM. High SURmax and MTV may indicate that the treatment planning should be tailored, which may improve patient prognosis.

Entities:  

Year:  2019        PMID: 31343610     DOI: 10.1097/MNM.0000000000001050

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

1.  18F-FDG PET/CT in diagnostic and prognostic evaluation of patients with cardiac masses: a retrospective study.

Authors:  Chunxia Qin; Fuqiang Shao; Fan Hu; Wenyu Song; Yangmeihui Song; Jinxia Guo; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-05       Impact factor: 9.236

2.  Characterization of 18F-fluorodeoxyglucose metabolic spatial distribution improves the differential diagnosis of indeterminate pulmonary nodules and masses with high fluorodeoxyglucose uptake.

Authors:  Jie Lin; Ling Wang; Xiaowei Ji; Xiangwu Zheng; Kun Tang
Journal:  Quant Imaging Med Surg       Date:  2021-04

3.  Modified method to improve the diagnostic efficiency of 18F-FDG PET/CT in regional lymph node metastasis of esophageal squamous cell carcinoma.

Authors:  Siqin Liao; Wenwei Wei; Shuliang Zhang; Taidui Zeng; Hao Chen; Wei Zheng; Chun Chen; Zhongyou Ji; Bin Zheng
Journal:  Ann Transl Med       Date:  2021-10

Review 4.  PET/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer.

Authors:  Danyu Ma; Ying Zhang; Xiaoliang Shao; Chen Wu; Jun Wu
Journal:  Curr Oncol       Date:  2022-09-11       Impact factor: 3.109

5.  Development and validation of a nomogram model for the prediction of 4L lymph node metastasis in thoracic esophageal squamous cell carcinoma.

Authors:  Lei Xu; Jia Guo; Shu Qi; Hou-Nai Xie; Xiu-Feng Wei; Yong-Kui Yu; Ping Cao; Rui-Xiang Zhang; Xian-Kai Chen; Yin Li
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.